3:24 PM
May 15, 2018
 |  BC Extra  |  Financial News

MediSix launches with $20M series A

Cell therapy company MediSix Therapeutics Pte. Ltd. (Singapore) launched with a $20 million series A round led by Lightstone Ventures. Temasek and Osage University Partners also participated. MediSix is developing preclinical CAR T cell therapies.

Last year, MediSix obtained an exclusive license to IP and technology from the National University of Singapore to develop therapies for T cell lymphoma and leukemia.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD